These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 20652697)

  • 1. Histological and immediate postoperative outcome after preoperative cetuximab: case-matched control study.
    Pessaux P; Marzano E; Casnedi S; Bachellier P; Jaeck D; Chenard MP
    World J Surg; 2010 Nov; 34(11):2765-72. PubMed ID: 20652697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted molecular therapies (cetuximab and bevacizumab) do not induce additional hepatotoxicity: preliminary results of a case-control study.
    Pessaux P; Panaro F; Casnedi S; Zeca I; Marzano E; Bachellier P; Jaeck D; Chenard MP
    Eur J Surg Oncol; 2010 Jun; 36(6):575-82. PubMed ID: 20452168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative Aspartate Aminotransferase-to-Platelet Ratio Index Predicts Perioperative Liver-Related Complications Following Liver Resection for Colorectal Cancer Metastases.
    Amptoulach S; Gross G; Sturesson C; Rissler P; Kalaitzakis E
    Scand J Surg; 2017 Dec; 106(4):311-317. PubMed ID: 28737112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histological and immediate postoperative outcome after preoperative cetuximab: case-matched control study.
    Spiliotis J; Zoras O
    World J Surg; 2011 May; 35(5):1153-4. PubMed ID: 21184075
    [No Abstract]   [Full Text] [Related]  

  • 5. Consequences of chemotherapy on resection of colorectal liver metastases.
    Pessaux P; Chenard MP; Bachellier P; Jaeck D
    J Visc Surg; 2010 Aug; 147(4):e193-201. PubMed ID: 20655821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases.
    Stremitzer S; Stift J; Singh J; Starlinger P; Gruenberger B; Tamandl D; Gruenberger T
    Eur J Surg Oncol; 2015 Jul; 41(7):868-74. PubMed ID: 25865557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases.
    Karoui M; Penna C; Amin-Hashem M; Mitry E; Benoist S; Franc B; Rougier P; Nordlinger B
    Ann Surg; 2006 Jan; 243(1):1-7. PubMed ID: 16371728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience.
    Wolf PS; Park JO; Bao F; Allen PJ; DeMatteo RP; Fong Y; Jarnagin WR; Kingham TP; Gönen M; Kemeny N; Shia J; D'Angelica MI
    J Am Coll Surg; 2013 Jan; 216(1):41-9. PubMed ID: 23041049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases.
    Pietrantonio F; Mazzaferro V; Miceli R; Cotsoglou C; Melotti F; Fanetti G; Perrone F; Biondani P; Muscarà C; Di Bartolomeo M; Coppa J; Maggi C; Milione M; Tamborini E; de Braud F
    Med Oncol; 2015 Jul; 32(7):182. PubMed ID: 26003673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histological liver injury and surgical outcome after FOLFOX followed by a hepatectomy for colorectal liver metastases in Japanese patients.
    Komori H; Beppu T; Baba Y; Horino K; Imsung C; Masuda T; Hayashi H; Okabe H; Ootao R; Watanabe M; Takamori H; Iyama K; Baba H
    Int J Clin Oncol; 2010 Jun; 15(3):263-70. PubMed ID: 20238233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome.
    Soubrane O; Brouquet A; Zalinski S; Terris B; Brézault C; Mallet V; Goldwasser F; Scatton O
    Ann Surg; 2010 Mar; 251(3):454-60. PubMed ID: 20160638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy.
    Adam R; Aloia T; Lévi F; Wicherts DA; de Haas RJ; Paule B; Bralet MP; Bouchahda M; Machover D; Ducreux M; Castagne V; Azoulay D; Castaing D
    J Clin Oncol; 2007 Oct; 25(29):4593-602. PubMed ID: 17925554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy.
    Nakano H; Oussoultzoglou E; Rosso E; Casnedi S; Chenard-Neu MP; Dufour P; Bachellier P; Jaeck D
    Ann Surg; 2008 Jan; 247(1):118-24. PubMed ID: 18156931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of attachment to or invasion of major intrahepatic vessels by colorectal liver metastases according to prehepatectomy chemotherapy regimen.
    Tanaka K; Nakagawa K; Yabushita Y; Hiroshima Y; Matsuo K; Ota M; Ichikawa Y; Taguri M; Tanabe M; Koda K; Endo I
    Surgery; 2014 May; 155(5):936-44. PubMed ID: 24656858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes of liver hemodynamic and elastography parameters in patients with colorectal liver metastases receiving preoperative chemotherapy: "a note of caution".
    Pelegrina A; Martí J; Miquel R; Ferrer J; Hernández-Gea V; Diaz A; Nadal C; García-Valdecasas JC; Fuster J
    World J Surg Oncol; 2017 Dec; 15(1):224. PubMed ID: 29246174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic atrophy following preoperative chemotherapy predicts hepatic insufficiency after resection of colorectal liver metastases.
    Yamashita S; Shindoh J; Mizuno T; Chun YS; Conrad C; Aloia TA; Vauthey JN
    J Hepatol; 2017 Jul; 67(1):56-64. PubMed ID: 28192187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined portal vein embolization and preoperative chemotherapy prior to liver resection for colorectal cancer metastases.
    Spelt L; Norman P; Törnqvist L; Tingstedt B; Andersson R
    Scand J Gastroenterol; 2012 Sep; 47(8-9):975-83. PubMed ID: 22631611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study.
    D'Angelica M; Kornprat P; Gonen M; Chung KY; Jarnagin WR; DeMatteo RP; Fong Y; Kemeny N; Blumgart LH; Saltz LB
    Ann Surg Oncol; 2007 Feb; 14(2):759-65. PubMed ID: 17103075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
    Folprecht G; Gruenberger T; Bechstein WO; Raab HR; Lordick F; Hartmann JT; Lang H; Frilling A; Stoehlmacher J; Weitz J; Konopke R; Stroszczynski C; Liersch T; Ockert D; Herrmann T; Goekkurt E; Parisi F; Köhne CH
    Lancet Oncol; 2010 Jan; 11(1):38-47. PubMed ID: 19942479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sinusoidal dilation increases the risk of complications in hepatectomy for CRCLM - Protective effect of bevacizumab and diabetes mellitus, serum gamma-glutamyltranspeptidase as predictive factor.
    Martins J; Alexandrino H; Oliveira R; Cipriano MA; Falcão D; Ferreira L; Martins R; Serôdio M; Martins M; Tralhão JG; Prado e Castro L; Castro E Sousa F
    Eur J Surg Oncol; 2016 May; 42(5):713-21. PubMed ID: 26972374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.